Patent 8,541,393 (US) Claim- and Scope-Based Landscape: Taurinamide (Taurolidine) + Citrate/Acid + Heparin Catheter Lock Solutions
US Drug Patent 8,541,393 claims a catheter locking solution that combines a taurinamide derivative (typically taurolidine) with an acid/citrate system that sets a specific pH window to enhance antimicrobial activity, plus heparin at a defined low-to-moderate unit range calibrated to reduce taurolidine reactions with stagnant blood without creating a high hemorrhage risk if the lock solution is expelled or spills into the patient’s bloodstream. The core novelty is the functional heparin concentration ceiling linked to hemorrhage risk and the pH-managed antimicrobial enhancement of the taurinamide system.
Because the claims you provided are tightly framed around (i) taurolidine/taurinamide, (ii) citrate or citric/lactic acid salts, (iii) pH 5.2–6.5, and (iv) heparin 50–2500 units/mL (with multiple nested sub-ranges), the enforceable scope concentrates on catheter lock products that are designed to treat catheter-related infection and patency loss/flow reduction while also addressing heparin-versus-antimicrobial compatibility and safety upon spillage.
What is US Patent 8,541,393 claiming for catheter lock solutions (taurolidine + citrate + heparin)?
Direct claim scope summary (claims 1–7, 11–20): the patent covers compositions and methods for treating and reducing infection and flow reduction in catheters using a locking solution comprising:
- A taurinamide derivative
- Claim set identifies taurolidine as the preferred embodiment in dependent claims (claims 3, 12, 17).
- A biologically acceptable acid and its corresponding salt that sets the lock solution pH to enhance antimicrobial activity of the taurinamide derivative
- Dependent claim 2 limits acid/salt pairing to citric acid + citrate or lactic acid + lactate.
- Dependent claim 3 narrows further to citric acid + citrate and pH 5.2 to 6.5.
- Heparin at 50 to 2500 units/mL, with a functional safety limitation tied to hemorrhage risk upon expulsion/spillage into blood
- Multiple dependent claims establish tighter heparin windows:
- claim 4: 50 to 1750 units/mL
- claim 5: 50 to 500 units/mL
- claim 6: 50 to 150 units/mL
Core functional boundaries:
- Heparin is present at enough level to prevent reactions of the taurinamide derivative with stagnant blood (claims 1 and 7; plus similar language in claim 16).
- Heparin is present at low enough level that expulsion/spillage carries a low risk of patient hemorrhage (claims 1, 7, 16).
Method claim (claim 7):
- Enhancing antimicrobial activity and resistance to flow reduction via:
- taurolidine + citrate and citric acid,
- maintaining pH 5.2–6.5,
- adding heparin 50–2500 units/mL with the same functional anti-reactivity/low-hemorrhage-risk framework.
Hemodialysis-specific composition claim (claim 11):
- Locks for hemodialysis catheters using taurinamide derivative + heparin 50–2500 units/mL with the same functional safety limitation.
H3: What do claims cover by product category?
- Broad catheter category (claims 1, 7, 16): “catheters” including those used in vascular access settings.
- Hemodialysis catheters explicitly (claims 11–15).
H3: What do claims require technologically?
- pH control to 5.2–6.5 (dependent claim 3; method claim 7 specifies this pH window).
- acid/salt pairing either citric/citrate or lactic/lactate (claim 2).
- taurolidine is required only in dependent claims (3, 7, 12, 17) but the independent claim uses “at least one taurinamide derivative.”
How broad is independent claim 1 vs method claim 7 in US 8,541,393?
Claim 1 breadth (composition-claims leverage):
- Requires all three elements:
- taurinamide derivative
- acid + salt combination that brings pH into an “enhances antimicrobial activity” range (functional language; not fixed unless you hit dependent claim 3)
- heparin 50–2500 units/mL, with functional anti-reactivity and low hemorrhage-risk limitations
What makes claim 1 broader than claim 7:
- Claim 1 does not force the specific pH 5.2–6.5 or the specific acid pair unless limited by dependent claim 2/3.
- Claim 1 does not force taurolidine (dependent claim 3 does).
What narrows enforceability in claim 1:
- The acid system and pH must be in a range that “enhances antimicrobial activity of the taurinamide derivative.” That phrase can be litigated as a claim-to-parameter linkage, requiring proof that an accused product achieves that functional antimicrobial-enhancement pH effect.
Claim 7 breadth (method-claims leverage):
- Locks taurolidine in combination with citrate/acid and requires:
- pH 5.2–6.5
- heparin 50–2500 units/mL with the same functional low hemorrhage-risk requirement
- It is narrower on pH and on acid pairing.
H3: Practical implication for design-arounds
A competitor looking to avoid literal infringement would focus on at least one of these axes:
- pH not in 5.2–6.5 (for method claim 7 and dependent composition claim 3/likely related limitations),
- acid/salt system not citric/citrate (or not meeting the claim-2 limitation) if they want to stay outside dependent claim territories,
- heparin concentration outside 50–2500 units/mL or redefining the product to eliminate “low hemorrhage risk” as a functional consequence (fact-specific),
- using a taurinamide derivative that is argued not to fall within “taurinamide derivative” as construed under the patent’s intrinsic record.
What dependent claim concentrations of heparin are protected (50–150 vs 50–500 vs 50–1750)?
US 8,541,393 contains a nested concentration ladder:
| Claim |
Scope element |
Heparin concentration |
| 1 |
Independent |
50 to 2500 units/mL |
| 4 |
Dependent on claim 1 |
50 to 1750 units/mL |
| 5 |
Dependent on claim 1 |
50 to 500 units/mL |
| 6 |
Dependent on claim 1 |
50 to 150 units/mL |
| 7 |
Method claim (requires pH 5.2–6.5 and taurolidine + citrate/citric acid) |
50 to 2500 units/mL |
| 8–10 |
Dependent on claim 7 |
50–1750, 50–500, 50–150 units/mL |
| 11 |
Hemodialysis composition |
50 to 2500 units/mL |
| 13–15 |
Dependent on claim 11 |
50–1750, 50–500, 50–150 units/mL |
| 16 |
Second independent-style composition (acid without specifying salt coupling) |
50 to 2500 units/mL |
| 18–20 |
Dependent on claim 16 |
50–1750, 50–500, 50–150 units/mL |
H3: Claim interplay that matters for infringement
If an accused product uses heparin within 50–150 units/mL, it falls inside:
- claim 1 and all dependent “50–150” variants (6, 10, 15, 20),
- and it also sits inside the “50–500” and “50–1750” dependent claims because those windows contain the 50–150 range.
That creates a strong likelihood of overlapping literal coverage depending on other required elements (taurolidine/acid/pH).
How does the pH limitation (5.2 to 6.5) constrain the patent’s enforceable scope?
Hard pH requirement appears in dependent claim 3 and method claim 7:
- claim 3: taurolidine + citric acid + citrate; pH 5.2 to 6.5
- claim 7: taurolidine + citrate and citric acid; pH 5.2 to 6.5
- independent claims 1 and 16 use functional “enhances antimicrobial activity” pH language, but the patent makes 5.2–6.5 explicit in at least one composition and the key method claim.
H3: What an accused product must show to avoid the pH-limited territory
- To avoid dependent claim 3 and method claim 7 literally, it can target pH below 5.2 or above 6.5 at use conditions.
- If the product uses pH outside 5.2–6.5, it may still fall into independent claim 1 if its pH is argued to be within the “enhances antimicrobial activity” range, which is not limited to 5.2–6.5 in claim 1/16.
Which acid systems are claimed: citric/citrate vs lactic/lactate?
Dependent claim 2 locks acid/salt pairing:
- biologically acceptable acid chosen from citric acid and lactic acid
- biologically acceptable salt chosen from citrate and lactate
This makes it easier to map accused formulations:
- If the formulation uses citric acid + citrate or lactic acid + lactate, it likely meets this dependency.
- If it uses a different buffer system (phosphate, acetate, etc.), it may avoid this dependent claim but could still face independent claim 1 if it satisfies the broader “acid + salt” functional pH/antimicrobial-enhancement requirement.
What is the patent coverage for hemodialysis catheters specifically?
Claim 11 narrows to hemodialysis:
- “A composition for treating and reducing infection and patency loss in hemodialysis catheters”
- locking solution includes:
- at least one taurinamide derivative
- heparin 50–2500 units/mL
- with the functional anti-reactivity and low hemorrhage-risk limitation
Dependent claims 12–15 identify:
- taurolidine (claim 12)
- heparin windows 50–1750, 50–500, 50–150 (claims 13–15)
H3: Product mapping
Hemodialysis lock solutions by category typically distinguish:
- antimicrobial actives (e.g., taurolidine/citrate systems),
- anticoagulant components (heparin or alternatives),
- buffer/pH system.
US 8,541,393 is designed to capture the overlap between antimicrobial taurinamides and heparin at defined unit concentrations.
What patent estate risks exist for generics and follow-on lock solutions if they copy the formulation?
This patent is not framed as a method-of-manufacture patent. It is a formulation and method-of-use style patent. That creates a high risk profile for follow-on products that replicate:
- taurolidine or a taurinamide derivative,
- citrate/citric acid or the claimed acid/salt pairing,
- pH around 5.2–6.5,
- heparin concentration 50–2500 units/mL with the “low hemorrhage risk” functional profile.
H3: Design-around pressure points (high leverage)
- Remove or substantially alter heparin concentration out of 50–2500 units/mL.
- Replace heparin with a different anticoagulant strategy (argued outside the literal “heparin” element).
- Adjust buffering and pH to avoid the 5.2–6.5 band for method/dependent composition territory.
- Use a different acid/salt pair to avoid claim 2 and claim 3 (though claim 1/16 functional pH language may still be a challenge).
How strong is the patent’s claim construction posture based on the claim text provided?
On the face of the claims, the enforceable scope is meaningful but not unlimited:
Strength indicators
- Multiple explicit parameter ranges: pH 5.2–6.5 and heparin 50–2500 units/mL plus nested sub-ranges.
- Specific acid/salt dependencies: citric/citrate and lactic/lactate.
- Functionally limited safety element tied to low hemorrhage risk upon spillage. This can be used in infringement to argue the accused formulation retains the same safety profile.
Vulnerability indicators
- Independent claim 1 and claim 16 contain a functional antimicrobial-enhancement pH phrase (“enhances antimicrobial activity”) rather than a fixed pH, which can increase litigation disputes over whether the accused pH falls within the claimed functional range.
- “Low risk of patient hemorrhage” is inherently fact-intensive and may be attacked on clinical evidence, formulation behavior, or use conditions.
Still, the presence of hard ranges (especially pH 5.2–6.5) and hard numeric heparin windows makes the patent more “map-able” than a purely conceptual antimicrobial-stabilization claim.
What other patents are likely involved (process, related formulations, and prior art clusters)?
The patent text you provided contains formulation and method-of-use claim elements that commonly sit inside a broader patent family around:
- taurolidine lock solutions,
- buffer systems to manage taurolidine activity,
- anticoagulant compatibility (heparin dose windows),
- catheter infection and patency endpoints (catheter-related bloodstream infection and thrombosis/occlusion analogs).
However, without the US patent record for 8,541,393 (family members, continuations, and cited references), no accurate, data-backed landscape by patent number can be produced.
How would a court likely analyze infringement for a taurolidine + citrate + heparin lock solution product?
For literal infringement, a typical element-by-element match would proceed as follows:
- Is there a “locking solution composition” for catheter use?
- Does it include at least one taurinamide derivative (taurolidine is the clearest candidate)?
- Is there an acid system with biologically acceptable acid and corresponding salt that results in a pH that enhances antimicrobial activity?
- Is there heparin at 50–2500 units/mL?
- Does the formulation satisfy the functional constraints:
- prevents taurinamide reactions with stagnant blood
- maintains low hemorrhage risk upon expulsion/spillage
A product that matches the explicit dependent claim set (e.g., taurolidine + citric acid/citrate + pH 5.2–6.5 + heparin 50–150 or 50–500) has the most straightforward mapping.
Key Takeaways
- US 8,541,393 protects catheter lock solutions that pair taurolidine (taurinamide) with a citrate/acid pH-controlled antimicrobial-enhancing system and heparin dosed to block taurolidine-stagnant-blood reactions while limiting hemorrhage risk on spillage.
- The most enforceable and litigation-friendly constraints are the numeric heparin ranges (50–2500 units/mL with nested 50–1750/500/150) and the explicit pH 5.2–6.5 (dependent claim 3 and method claim 7).
- For product teams, the highest-risk similarity triggers are:
- heparin inclusion in 50–2500 units/mL, and
- pH in 5.2–6.5 with citric/citrate and taurolidine.
- The independent claim 1/16 functional “antimicrobial-enhancement pH” and “low hemorrhage risk” language can still drive disputes, but the claim architecture is designed to create measurable formulation constraints that are testable in enforcement.
FAQs
-
Does US 8,541,393 require taurolidine specifically?
No. Independent claims require “at least one taurinamide derivative.” Taurolidine is expressly required in key dependent claims (e.g., claim 3) and in the method claim 7.
-
What heparin concentrations are explicitly within the protected range?
The claims cover 50–2500 units/mL, with dependent sub-ranges of 50–1750, 50–500, and 50–150 units/mL.
-
Is the pH limitation optional or fixed?
The pH 5.2–6.5 is fixed in dependent claim 3 and method claim 7. Independent claim 1 uses a functional pH-enhancement requirement rather than a fixed pH window.
-
Do the claims cover both citric/citrate and lactic/lactate buffers?
Yes. Dependent claim 2 covers citric acid/citrate and lactic acid/lactate.
-
Are hemodialysis catheters specifically covered?
Yes. Claim 11 is directed to locking solutions for hemodialysis catheters and limits the formulation to taurinamide + heparin at 50–2500 units/mL with the stated functional constraints.
References (APA)
No external sources were provided or cited in the request; none are included.
